Location · Chicago, IL
Clinical trials in Chicago, IL
738 recruiting studies have a site in the Chicago area, and 232 of them accept healthy volunteers. The area includes Evanston, Oak Brook, Oak Lawn, Park Ridge, Skokie, Maywood and nearby cities.
738 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 3
Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease
Vor Biopharma
- Location
- Chandler, AZ + 46 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2
Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus
Hanmi Pharmaceutical Company Limited
- Location
- Mesa, AZ + 19 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
An Open-label Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome
Neuren Pharmaceuticals Limited
- Location
- Birmingham, AL + 10 other US sites
- Eligibility basics
- Ages 3–12
- Recruiting
Maturation of Arteriovenous Fistula With Automated Sonography Assessments Trial
Sonavex, Inc.
- Location
- Dothan, AL + 19 other US sites
- Eligibility basics
- Ages 18–84
- RecruitingPhase 2/Phase 3
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
Cabaletta Bio
- Location
- New Haven, CT + 9 other US sites
- Eligibility basics
- Ages 18–75
- Recruiting
Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)
Abbott Medical Devices
- Location
- Birmingham, AL + 24 other US sites
- Eligibility basics
- Ages 22–70
- RecruitingPhase 3
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
Cybin IRL Limited
- Location
- Birmingham, AL + 27 other US sites
- Eligibility basics
- Ages 18–85
- RecruitingPhase 3
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Hoffmann-La Roche
- Location
- Dothan, AL + 91 other US sites
- Eligibility basics
- Ages 16–80
- RecruitingPhase 3
A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia
Crinetics Pharmaceuticals Inc.
- Location
- Los Angeles, CA + 12 other US sites
- Eligibility basics
- Ages 18–74
- RecruitingPhase 2/Phase 3
A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)
Crinetics Pharmaceuticals Inc.
- Location
- San Francisco, CA + 9 other US sites
- Eligibility basics
- Ages 1–17
- RecruitingPhase 3
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
Sanofi
- Location
- Tucson, AZ + 36 other US sites
- Eligibility basics
- Ages 16–80
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safey of PTP-001 (MOTYS™) in Knee Osteoarthritis Patients (MOTION-P)
Doron Therapeutics Inc.
- Location
- Birmingham, AL + 7 other US sites
- Eligibility basics
- Ages 40–80
- RecruitingPhase 2
A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Sanofi
- Location
- Scottsdale, AZ + 19 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2/Phase 3
Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema
AbbVie
- Location
- Mesa, AZ + 36 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine
Kallyope Inc.
- Location
- Birmingham, AL + 111 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 1/Phase 2
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With…
Cabaletta Bio
- Location
- Redwood City, CA + 9 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2/Phase 3
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
Cabaletta Bio
- Location
- Orange, CA + 29 other US sites
- Eligibility basics
- Ages 6–75
- RecruitingPhase 3
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Akero Therapeutics, Inc
- Location
- Birmingham, AL + 131 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
Novartis Pharmaceuticals
- Location
- Birmingham, AL + 16 other US sites
- Eligibility basics
- Ages 12–100
- Recruiting
Infant Formula in Infants and Children With Cow's Milk Allergy
Abbott Nutrition
- Location
- Phoenix, AZ + 7 other US sites
- Eligibility basics
- Ages 4 mo–12
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
UCB Biopharma SRL
- Location
- Avondale, AZ + 61 other US sites
- Eligibility basics
- Ages 16+
- RecruitingPhase 3
Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy
Vertex Pharmaceuticals Incorporated
- Location
- Anniston, AL + 57 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
Sanofi
- Location
- Birmingham, AL + 20 other US sites
- Eligibility basics
- Ages 10–65
- RecruitingPhase 3
A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.
Pfizer
- Location
- Irvine, CA + 18 other US sites
- Eligibility basics
- Ages 6–14